|
|
|
 |
|
|
|
|
|
|
 |
Aprovel®, a new hypertensive agent from Sanofi research is launched in France |
|
|
| Jan. 29, 98 |
|
|
|
|
|
|
|
|
After receiving marketing approval in Europe in August 1997 and in the US in October 1997, Aprovel® (irbesartan), a new hypertensive agent from Sanofi Research, has been marketed in France since January 16, 1998 by the sales forces of Sanofi and Bristol-Myers Squibb.
Aprovel® has been co-developed by Sanofi and Bristol-Myers Squibb since 1993. It is a powerful and selective angiotensin II receptor antagonist (AIIRA), a new class of medicines for the treatment of hypertension.
This anti-hypertensive agent has shown efficacy that increases with dose, while maintaining placebo-level tolerability at all doses.
Aprovel® was first marketed in the UK and Germany in September 1997, and then was launched in other European countries: the Netherlands, Sweden, Denmark and Finland. The US launch took place in early November 1997.
Sales of Aprovel® generated by Sanofi and Bristol-Myers Squibb in 1997 amounted to FRF 140 million.
Aprovel® will soon be launched in Italy and in Spain.
|
|
|
|
|
|
|
|
|
|
